الفهرس | Only 14 pages are availabe for public view |
Abstract Curcumin is an active ingredient in turmeric, which is a highly potent, non-toxic, and bioactive agent. It has been used as a home remedy for many diseases for decades. Curcumin is safe and effective in diseases such as autoimmune, cardiac, neoplasm, respiratory, neurodegenerative cancer, and metabolic disorders. The medical properties are due to its anti-inflammation, anti-tumor, antioxidant and immune-enhancing activity. Curcumin has an immuno-modulatory effect, such as the regulation of cell reactions and the production of various immune-specific cell forms, including T and B cells and phagocytic cells. Curcumin has the ability to lower TNF-α and IL-6 levels and to modulate a number of different growth factors, transcription factors, cytokines and different enzymes. The availability of useful animal models reflecting the human obesity syndrome is crucial in the search for novel compounds for the pharmacological treatment of obesity. This work was designed to Determine the gene expression of MCP1 and IL-6 in the pancreas, liver and S/C adipose tissues and investigate suggested immuno-modulatory and protective effects of curcumin via determining the changes in mRNA expression of MCP1 and IL6 in the pancreas, liver and S/C adipose tissues in induced metabolic syndrome (MS) rat model. In the current study, we have performed an extensive characterization of the obesity syndrome in a male rats as the animal model. rats were fed either a high-far sugar diet (HFSD) or a standard chow (Chow) diet for 9 months. Metabolic characterization including blood biochemistry and glucose homeostasis was examined. Furthermore, after 3 month, the anti-diabetic/obesity effects of metformin and curcumin were examined. HFSD rats developed visceral obesity, hyperleptinemia, and hyperinsulinemia. |